[1] Péchoux CL, Mercier O, Belemsagha D, Bouaita R, Besse B, Fadel E. Role of Adjuvant Radiotherapy in Completely Resected Non-Small-Cell Lung Cancer. EJC Suppl 2013;11:123-30.

[2] Chemotherapy in Non-Small Cell Lung Cancer: A MetaAnalysis Using Updated Data on Individual Patients from 52 Randomised Clinical Trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.

[3] Postoperative Radiotherapy in Non-Small-Cell Lung Cancer: Systematic Review and Meta-Analysis of Individual Patient Data from Nine Randomised Controlled Trials. PORT Meta-Analysis Trialists Group. Lancet 1998;352:257-63.

[4] Rami-Porta R, Wittekind C, Goldstraw P, International Association for the Study of Lung Cancer (IASLC) Staging Committee. Complete Resection in Lung Cancer Surgery: Proposed Definition. Lung Cancer 2005;49:25-33.

[5] Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, et al. Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected NonSmall-Cell Lung Cancer. N Engl J Med 2004;350:351-60.

[6] Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared with Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. J Clin Oncol 2010;28:29-34.

[7] Douillard JY, Rosell R, de Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant Vinorelbine Plus Cisplatin Versus Observation in Patients with Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A Randomised Controlled Trial. Lancet Oncol 2006;7:719-27.

[8] Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.

[9] Booth CM, Shepherd FA, Peng Y, Darling G, Li G, KongW, et al. Time to Adjuvant Chemotherapy and Survival in Non-Small Cell Lung Cancer: A Population-Based Study. Cancer 2013;119:1243-50.

[10] van Houtte P, Rocmans P, Smets P, Goffin JC, LustmanMaréchal J, Vanderhoeft P, et al. Postoperative Radiation Therapy in Lung Caner: A Controlled Trial after Resection of Curative Design. Int J Radiat Oncol Biol Phys 1980;6:983-6.

[11] Trodella L, Granone P, Valente S, Valentini V, Balducci M, Mantini G, et al. Adjuvant Radiotherapy in Non-Small Cell Lung Cancer with Pathological Stage I: Definitive Results of a Phase III Randomized Trial. Radiother Oncol 2002;62:11-9.

[12] Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, et al. Postoperative Radiation Therapy is Associated with Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. J Clin Oncol 2015;33:2727-34.

[13] Burdett S, Rydzewska L, Tierney J, Fisher D, Parmar MK, Arriagada R, et al. Postoperative Radiotherapy for NonSmall Cell Lung Cancer. Cochrane Database Syst Rev 2003;1:CD002142.

[14] Higgins KA, Chino JP, Berry M, Ready N, Boyd J, Yoo DS, et al. Local Failure in Resected N1 Lung Cancer: Implications for Adjuvant Therapy. Int J Radiat Oncol Biol Phys 2012;83:727-33.

[15] Guerra JL, Gomez DR, Lin SH, Levy LB, Zhuang Y, Komaki R, et al. Risk Factors for Local and Regional Recurrence in Patients with Resected N0-N1 Non-SmallCell Lung Cancer, with Implications for Patient Selection for Adjuvant Radiation Therapy. Ann Oncol 2013;24:67-74.

[16] Lung Cancer Study Group. Effects of Postoperative Mediastinal Radiation on Completely Resected Stage II and Stage III Epidermoid Cancer of the Lung. N Engl J Med 1986;315:1377-81.

[17] Stephens RJ, Girling DJ, Bleehen NM, Moghissi K, Yosef HM, Machin D. The Role of Post-Operative Radiotherapy in Non-Small-Cell Lung Cancer: A Multicentre Randomised Trial in Patients with Pathologically Staged T1-2, N1-2, M0 Disease. Medical Research Council Lung Cancer Working Party. Br J Cancer 1996;74:632-9.

[18] Feng QF, Wang M, Wang LJ, Yang ZY, Zhang YG, Zhang DW, et al. A Study of Postoperative Radiotherapy in Patients with Non-Small-Cell Lung Cancer: A Randomized Trial. Int J Radiat Oncol Biol Phys 2000;47:925-9.

[19] Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative Radiotherapy for Stage II or III Non-Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database. J Clin Oncol 2006;24:2998-3006.

[20] Zou B, Xu Y, Li T, Li W, Tang B, Zhou L, et al. A Multicenter Retrospective Analysis of Survival Outcome Following Postoperative Chemoradiotherapy in NonSmall-Cell Lung Cancer Patients with N2 Nodal Disease. Int J Radiat Oncol Biol Phys 2010;77:321-8.

[21] NSCLC Meta-Analyses Collaborative Group, Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, et al. Adjuvant Chemotherapy, With or Without Postoperative Radiotherapy, in Operable Non-Small-Cell Lung Cancer: Two Meta-Analyses of Individual Patient Data. Lancet 2010;375:1267-77.

[22] Corso CD, Rutter CE, Wilson LD, Kim AW, Decker RH, Husain ZA. Re-Evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non-Small-Cell Lung Cancer Using the National Cancer Database. J Thorac Oncol 2015;10:148-55.

[23] Mikell JL, Gillespie TW, Hall WA, Nickleach DC, Liu Y, Lipscomb J, et al. Postoperative Radiotherapy is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the National Cancer Data Base. J Thorac Oncol 2015;10:462-71.

[24] Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, et al. Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated with Adjuvant Chemotherapy: A Review of the National Cancer Data Base. J Clin Oncol 2015;33:870-6.

[25] Billiet C, Decaluwé H, Peeters S, Vansteenkiste J, Dooms C, Haustermans K, et al. Modern Post-Operative Radiotherapy for Stage III Non-Small Cell Lung Cancer May Improve Local Control and Survival: A MetaAnalysis. Radiother Oncol 2014;110:3-8.

[26] Francis S, Orton A, Stoddard G, Tao R, Hitchcock YJ, Akerley W, et al. Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. J Clin Oncol 2018;36:333-41.

[27] Selek U, Chang JY. Optimal Sequencing of Postoperative Radiotherapy and Chemotherapy in IIIA-N2 Non-Small Cell Lung Cancer. J Thorac Dis 2016;8:1394-7.

[28] Kepka L, Socha J, Rucinska M, Wasilewska-Tesluk E, Komosinska K. Sequencing Postoperative Radiotherapy and Adjuvant Chemotherapy in Non-Small Cell Lung Cancer: Unanswered Questions on the Not EvidenceBased Approach. J Thorac Dis 2016;8:1381-5.

[29] Lee HW, Noh OK, Oh YT, Choi JH, Chun M, Kim HI, et al. Radiation Therapy-First Strategy After Surgery With or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2016;94:621-7.

[30] Liu T, Mu Y, Dang J, Li G. The Role of Postoperative Radiotherapy for Completely Resected pIIIA-N2 Non-Small Cell Lung Cancer Patients with Different Clinicopathological Features: A Systemic Review and Meta-Analysis. J Cancer 2019;10:3941-9.

[31] NICE Guidelines; 2019. Available from: https://www.nice. org.uk/guidance/ng122.[Last accessed on 2020 Sep 01].

[32] NCCN Guidelines, v8-2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. [Last accessed on 2020 Sep 01].

[33] Spoelstra FO, Senan S, Le Péchoux C, Ishikura S, Casas F, Ball D, et al. Variations in Target Volume Definition for Postoperative Radiotherapy in Stage III Non-Small-Cell Lung Cancer: Analysis of an International Contouring Study. Int J Radiat Oncol Biol Phys 2010;76:1106-13.

[34] Gómez A, González JA, Couñago F, Vallejo C, Casas F, de Dios NR. Evidence-Based Recommendations of Postoperative Radiotherapy in Lung Cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clin Transl Oncol 2016;18:331-41.

[35] Olszyna-Serementa M, Socha J, Wierzchowski M, KępkaL. Patterns of Failure after Postoperative Radiotherapy for Incompletely Resected (R1) Non-Small Cell Lung Cancer: Implications for Radiation Target Volume Design. Lung Cancer 2013;80:179-84.

[36] Le Pechoux C, Pourel N, Barlesi F, Faivre-Finn C, Lerouge D, Zalcman G, et al. Phase III Study Comparing Post-Operative Conformal Radiotherapy to No PostOperative Radiotherapy in Patients With Completely Resected Non-Small Cell Lung Cancer and Mediastinal N2 Involvement [Lung ART] ESMO; 2020.

[37] Hui Z, Men Y, Hu C. Phase III Comparison of Postoperative 3D Conform Radiotherapy after Chemotherapy and Chemotherapy Alone in Patients with Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer. J Thorac Oncol 2019;14:S238-S9.

[38] Rossi A. Adjuvant Therapy in Early-Stage Small-Cell Lung Cancer: What’s New? Transl Cancer Res 2016;5:S166-9.

[39] Valliers E. Role of Surgery in Multimodality Therapy for Small Cell Lung Cancer; 2020. Available from: https:// www.uptodate.com. [Last accessed on 2020 Sep 01].

[40] Jackman DM, Johnson BE. Small-Cell Lung Cancer. Lancet 2005;366:1385-96.

[41] Fox W, Scadding JG. Medical Research Council Comparative Trial of Surgery and Radiotherapy for Primary Treatment of Small-Celled or Oat-Celled Carcinoma of Bronchus. Ten-Year Follow-Up. Lancet 1973;2:63-5.

[42] Schreiber D, Rineer J, Weedon J, Vongtama D, Wortham A, Kim A, et al. Survival Outcomes with the Use of Surgery in Limited-Stage Small Cell Lung Cancer: Should Its Role be Re-Evaluated? Cancer 2010;116:1350-7.

[43] Yu JB, Decker RH, Detterbeck FC, Wilson LD. Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer. J Thorac Oncol 2010;5:215-9.

[44] Wakeam E, Acuna SA, Leighl NB, Giuliani ME, Finlayson SR, Varghese TK, et al. Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival. Lung Cancer 2017;109:78-88.

[45] Inoue M, Miyoshi S, Yasumitsu T, Mori T, Iuchi K, Maeda H, et al. Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System. Thoracic Surgery Study Group of Osaka University, Osaka, Japan. Ann Thorac Surg 2000;70:1615-9.

[46] Rostad H, Naalsund A, Jacobsen R, Strand TE, Scott H, Strøm EH, et al. Small Cell Lung Cancer in Norway. Should More Patients Have Been Offered Surgical Therapy? Eur J Cardiothorac Surg 2004;26:782-6.

[47] Brock MV, Hooker CM, Syphard JE, Westra W, Xu L, Alberg AJ, et al. Surgical Resection of Limited Disease Small Cell Lung Cancer in the New Era of Platinum Chemotherapy: Its Time has Come. J Thorac Cardiovasc Surg 2005;129:64-72.

[48] Lim E, Belcher E, Yap YK, Nicholson AG, Goldstraw P. The Role of Surgery in the Treatment of Limited Disease Small Cell Lung Cancer: Time to Reevaluate. J Thorac Oncol 2008;3:1267-71.

[49] Schneider BJ, Saxena A, Downey RJ. Surgery for EarlyStage Small Cell Lung Cancer. J Natl Compr Canc Netw 2011;9:1132-9.

[50] Karrer K, Shields TW, Denck H, Hrabar B, Vogt-Moykopf I, Salzer GM. The Importance of Surgical and Multimodality Treatment for Small Cell Bronchial Carcinoma. J Thorac Cardiovasc Surg 1989;97:168-76.

[51] Merkle NM, Mickisch GH, Kayser K, Drings P, VogtMoykopf I. Surgical Resection and Adjuvant Chemotherapy for Small Cell Carcinoma. Thorac Cardiovasc Surg 1986;34:39-42.

[52] Osterlind K, Hansen M, Hansen HH, Dombernowsky P. Influence of Surgical Resection Prior to Chemotherapy on the Long-Term Results in Small Cell Lung Cancer. A Study of 150 Operable Patients. Eur J Cancer Clin Oncol 1986;22:589-93.

[53] Shepherd FA, Ginsberg RJ, Feld R, Evans WK, Johansen E. Surgical Treatment for Limited Small-Cell Lung Cancer. The University of Toronto Lung Oncology Group Experience. J Thorac Cardiovasc Surg 1991;101:385-93.

[54] Macchiarini P, Hardin M, Basolo F, Bruno J, Chella A, Angeletti CA. Surgery Plus Adjuvant Chemotherapy for T1-3N0M0 Small-Cell Lung Cancer. Rationale for Current Approach. Am J Clin Oncol 1991;14:218-24.

[55] Karrer K, Ulsperger E. Surgery for Cure Followed by Chemotherapy in Small Cell Carcinoma of the Lung. For the ISC-Lung Cancer Study Group. Acta Oncol 1995;34:899-906.

[56] Rea F, Callegaro D, Favaretto A, Loy M, Paccagnella A, Fantoni U, et al. Long Term Results of Surgery and Chemotherapy in Small Cell Lung Cancer. Eur J Cardiothorac Surg 1998;14:398-402.

[57] Tsuchiya R, Suzuki K, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N, et al. Phase II Trial of Postoperative Adjuvant Cisplatin and Etoposide in Patients with CompletelyResected Stage I-IIIa Small Cell Lung Cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005;129:977-83.

[58] Yang CF, Chan DY, Speicher PJ, Gulack BC, Wang X, Hartwig MG, et al. Role of Adjuvant Therapy in a Population-Based Cohort of Patients with Early-Stage Small-Cell Lung Cancer. J Clin Oncol 2016;34:1057-64.

[59] Yang CF, Chan DY, Yerokun B, Wang X, Tong BC, Dámico T, et al. Surgery Versus Optimal Medical Management of EarlyStage Small Cell Lung Cancer. J Clin Oncol 2016;34:8511.

[60] Wong AT, Rineer J, Schwartz D, Schreiber D. Assessing the Impact of Postoperative Radiation Therapy for Completely Resected Limited-Stage Small Cell Lung Cancer Using the National Cancer Database. J Thorac Oncol 2016;11:242-8.

[61] Wakeam E, Giuliani M, Leighl NB, Finlayson SR, Varghese TK, Darling GE. Indications for Adjuvant Mediastinal Radiotherapy in Surgically Resected Small Cell Lung Cancer. Ann Thorac Surg 2017;103:1647-53.

[62] Engelhardt KE, Coughlin JM, DeCamp MM, Denlinger CE, Meyerson SL, Bharat A, et al. Survival after Adjuvant Radiation Therapy in Localized Small Cell Lung Cancer Treated with Complete Resection. J Thorac Cardiovasc Surg 2019;158:1665-77.e2.

[63] Putora PM, de Ruysscher D, Glatzer M, Widder J, van Houtte P, Troost EG, et al. The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts. Radiother Oncol 2020;145:45-8.

[64] NCCN Guidelines, v1.2021. Available from: https://www. nccn.org/professionals/physician_gls/pdf/sclc.pdf .[Last accessed on 2020 Sep 01].

[65] Le Pechoux C, Faivre-Finn C, Ramella S, McDonald F, Manapov F, Putora PM, et al. ESTRO ACROP Guidelines for Target Volume Definition in the Thoracic Radiation Treatment of Small Cell Lung Cancer. Radiother Oncol 2020;152:89-95.